Word

RNA DESIGN OPTUDIO

Status

Pending

Status Code

686

Status Date

Tuesday, September 24, 2024

Serial Number

98211080

Mark Type

4

Filing Date

Thursday, October 5, 2023

Published for Opposition

Tuesday, September 24, 2024

Trademark Owner History

Samsung Biologics Co., Ltd. - Owner At Publication

Classifications

9 DNA analysis apparatus, namely, medical laboratory research instruments for DNA analysis; DNA chips; RNA microarrays; cartridges for storing specimen used for RNA analysis apparatus, namely, solid phase extraction cartridges for laboratory use; reagent cartridges used for RNA analysis apparatus, namely, solid phase extraction cartridges for laboratory use; reagent containers used for RNA analysis apparatus, namely, solid phase extraction cartridges for laboratory use; RNA analysis apparatus, namely, medical laboratory research instruments for RNA analysis; RNA sequencing devices, namely, laboratory devices for detecting genetic sequences; RNA chips; genome analyzer machines, namely, laboratory devices for detecting genetic sequences and related downloadable computer operating software; devices for analyzing genome information, namely, laboratory devices for detecting genetic sequences; bioreactors for cell culturing for scientific research; biochip analyzing apparatus for research or scientific purposes; biochip sensors for sensing antigens; biochips for research or scientific purposes; liquid dosage devices that measure the amounts to be dispensed, namely, dispensers for measuring and dispensing of distilled water, not for medical use; incubators for cell culture, not for medical purposes; cellchip inspectors being optical inspection apparatus; devices for analyzing protein sequence used as laboratory apparatus, namely, laboratory devices for detecting genetic sequences; physical and chemical machines for laboratory use; physical and chemical apparatus for analyzing genes, namely, laboratory devices for detecting genetic sequences; gene amplifiers being DNA microarrays; mRNA microarrays; RNA, DNA, and mRNA microarrays; nucleic acid sequencing devices and nucleic acid synthetic apparatus, namely, laboratory devices for detecting genetic sequences; diagnostic chips for inspecting blood plasma laboratory apparatus, namely, DNA chips; diagnostic chips for analyzing blood plasma laboratory apparatus, namely, DNA chips

5 Reagents for medical use for measurement of HBs antibody; medicines consisting of RNA for treating cancer; crude medicines for treating ocular diseases; cellular function activating agents for medical purposes; colostral antibodies for veterinary purposes; chemico-pharmaceutical preparations for treating cancer; chemical preparations for use in DNA analysis for medical purposes; chemical preparations for use in RNA analysis for medical purposes; bacterial preparations for medical and veterinary use; chemical preparations for treating cancer for medical or veterinary purposes; biotechnological preparations for medical purposes, namely, reagents for medical purposes; biological reagents for medical purposes; Biochemical preparations for the medical treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorder; reagents for medical use; bispecific colostral antibody for medical use; trace element preparations being dietary supplements for human use; clinical medical reagents; pharmaceutical preparations for the treatment of cancer; medical diagnostic reagents for the detection of mRNA antigens; colostral antibodies for medical purposes

42 RNA technology research and development; providing temporary use of non-downloadable web application for sharing information in the RNA technology field; research in the field of RNA repair technology; research and development of RNA chips; research relating to science, namely, scientific research in the field of RNA; RNA screening for scientific research purposes; RNA sequence analysis for scientific research purposes; multiple nucleic acid analysis for scientific research purposes; molecular analysis for scientific research purposes; development of new technology for others in the field of biotechnology; biochemical analysis; drug discovery services; design of new products for others; pharmaceutical research and development; clinical studies of medicines, namely, conducting clinical trials for others; services for assessing the efficiency of pharmaceuticals, namely, product quality testing services; fusion protein analysis for scientific research purposes; computer programming services in the medical field; medical laboratories; management assistance services for medical image data, namely, engineering services; medicine research being medical research; analysis and evaluation of medical product development, namely, product quality testing services; providing scientific information on the testing, inspection and research of medical products; scientific and medical laboratory services relating to the production of bispecific antibody antibodies; pharmaceutical drug development for bispecific antibody; bispecific antibody research and development; evaluating of clinical trial progress, namely, conducting clinical trials for others; clinical trials, namely, conducting clinical trials for others; providing temporary use of online, non-downloadable computer operating software for genome analyzer machines

"RNA DESIGN"

Trademark Events

Oct 9, 2023

New Application Entered

Oct 14, 2023

New Application Office Supplied Data Entered

Oct 30, 2023

Assigned To Examiner

Nov 7, 2023

Non-Final Action Written

Nov 7, 2023

Non-Final Action E-Mailed

Nov 7, 2023

Notification Of Non-Final Action E-Mailed

Jan 31, 2024

Teas Response To Office Action Received

Jul 19, 2024

Correspondence Received In Law Office

Jul 18, 2024

Assigned To Lie

Jul 19, 2024

Teas/Email Correspondence Entered

Aug 20, 2024

Non-Final Action Written

Aug 20, 2024

Non-Final Action E-Mailed

Aug 21, 2024

Examiner's Amendment Entered

Aug 21, 2024

Notification Of Examiners Amendment E-Mailed

Aug 21, 2024

Examiners Amendment -Written

Aug 21, 2024

Examiners Amendment E-Mailed

Aug 22, 2024

Approved For Pub - Principal Register

Sep 4, 2024

Notification Of Notice Of Publication E-Mailed

Sep 24, 2024

Published For Opposition

Sep 24, 2024

Official Gazette Publication Confirmation E-Mailed

Aug 20, 2024

Notification Of Non-Final Action E-Mailed